March 10, 2022

Press release

FluoGuide intends to carry out a directed share issue of approximately SEK 25 million

Copenhagen, Denmark, 17:31 CEST, 10 March 2022 – FluoGuide A/S (publ), a developer of surgical precision solutions within oncology (“FluoGuide” or... [Read more]

December 22, 2021

Press release

FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer

Copenhagen, Denmark, 22 December 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has submitted... [Read more]

November 19, 2021

Press release

ABG Sundal Collier initiates equity research on FluoGuide

Copenhagen, Denmark, 19 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Swedish investment bank... [Read more]

November 15, 2021

Press release

FluoGuide A/S publishes interim report for the period January – September 2021

Copenhagen, Denmark, 15 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]

November 10, 2021

Press release

FluoGuide selects lung cancer as the next indication for FG001 and will initiate phase II trial in the beginning of 2022

Copenhagen, Denmark, 10 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has selected... [Read more]

November 9, 2021

Press release

Publication of a case report showing first promising clinical data on FG001s use in treatment of meningioma brain tumor

Copenhagen, Denmark, 9 November 2021. FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce the publication of a clinical case... [Read more]

November 1, 2021

Press release

FluoGuide initiates preclinical development with FG002

Copenhagen, Denmark, 1 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today is pleased to announce the initiation of the... [Read more]

October 12, 2021

Press release

Redeye initiates commissioned research on FluoGuide

Copenhagen, Denmark, 12 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) has entered into an agreement with the Swedish investment... [Read more]

October 8, 2021

Press release

FG001 is proven safe in patients undergoing surgery for cancer – a significant milestone for FluoGuide to further advance clinical development in aggressive brain cancer and in a prevalent indication

Copenhagen, Denmark, 8 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 has been concluded... [Read more]